PD-L1 Negative Advanced Non-Small Cell Lung Cancer: Practice Patterns and Real-World Outcomes

Current Oncology 2026 Open access

Read full text
Authors: Audrey-Ann Bégin, Maude Dubé-Pelletier, Catherine Labbé, Vicky Mai, Michaël Maranda-Robitaille, Marie-Hélène Denault
DOI: 10.3390/curroncol33030144
Cited by: 0

Abstract

The standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) without oncogenic alterations and programmed death-ligand 1 (PD-L1) expression < 1% is a combination of chemotherapy (CT) and immunotherapy (IO). However, real-world overall survival (OS) appears more modest than in clinical trials, averaging 10–13 months. This retrospective study aimed to assess treatment patterns and real-world outcomes at the Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ). Patients diagnosed between January 2019 and December 2023 with advanced PD-L1

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Current Oncology
Volume
33
Issue
3
Pages
144–144
Publication date
28 February 2026
Language
EN